Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumor × niraparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 25 Prostatic Neoplasms 8 Fallopian Tube Neoplasms 8 Breast Neoplasms 7 Pancreatic Neoplasms 5 Neoplasm Metastasis 4 Endometrial Neoplasms 4 Neoplasms 3 Mesothelioma 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Glioblastoma 3 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Recurrence 2 Mesothelioma, Malignant 2 Melanoma 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Renal Cell 2 Uveal Melanoma 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Thrombocytopenia 1 Stomach Neoplasms 1 Solid Tumor 1 Sarcoma 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡